Agios Pharmaceuticals Licenses Cevidoplenib from Oscotec in a ~$165M Deal

Shots: Oscotec has granted Agios exclusive global rights to cevidoplenib (PO), a spleen tyrosine kinase inhibitor, across all indications, incl. immune thrombocytopenia (ITP) As per the deal, Agios will assume full development & commercialization costs, while Oscotec will receive $25M upfront, ~$140M in development & regulatory milestones across ~3 indications in the US & EU,…

ByRidhi Rastogi5 hours ago

NEWS

ADEL and Sanofi Ink ~$1.04B Global Licensing Deal for ADEL-Y01

Shots: ADEL has entered into an exclusive worldwide license agreement with Sanofi for the development & commercialization of ADEL-Y01 & related backup compounds As per the deal, ADEL will receive a non-refundable payment of $80M upfront plus development & commercial milestones, representing the total deal value of ~$1.04B, tiered royalties on net sales ranging up…

ByRidhi RastogiDecember 16, 2025

Agios Pharmaceuticals Licenses Cevidoplenib from Oscotec in a ~$165M Deal

ADEL and Sanofi Ink ~$1.04B Global Licensing Deal for ADEL-Y01

Contact US

FOLLOW US